Page 2 | Certara

Blog

QSP in Inflammatory Bowel Disease (IBD): From Biomarkers to Clinical Endpoints, with Virtual Patients

Certara supports IBD drug development with a QSP model that predicts Mayo score and CDAI…

CertaraFebruary 10, 2026

Announcement

Certara Introduces CRF Creator Module in Pinnacle 21® Enterprise for Faster Clinical Study Start-Up in Drug Development

Discover Pinnacle 21® Enterprise Plus' new CRF Creator module, designed to speed clinical study start-up…

CertaraFebruary 6, 2026

Press Coverage

Why Many Global Drugs Never Reach Japan

Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…

CertaraFebruary 5, 2026

Webinar

Ready for ESG NextGen, or still submitting like it’s 2015?

CertaraFebruary 5, 2026

Blog Knowledge Base

Trial Designs: Non-inferiority vs. Superiority vs. Equivalence

Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…

CertaraFebruary 3, 2026

Live Events

Phoenix Roadshow 2026 – Florence

CertaraFebruary 2, 2026

Publication

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…

CertaraFebruary 2, 2026

Blog

How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development

Quantitative Systems Pharmacology (QSP) helps address key challenges in Alzheimer’s disease drug development, including tau…

CertaraFebruary 2, 2026

Guide

Seeing is Understanding: Best Practices for Visualizing Nonclinical Study Data

SEND data visualization: best practices for visualizing nonclinical study data to reveal trends, spot outliers,…

CertaraFebruary 2, 2026

Press Coverage

Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach

Explore how a collaborative “sandbox” approach—combining flexible regulation, data modeling, and stakeholder engagement—can transform rare…

CertaraJanuary 30, 2026

QSP in Inflammatory Bowel Disease (IBD): From Biomarkers to Clinical Endpoints, with Virtual Patients

Certara Introduces CRF Creator Module in Pinnacle 21® Enterprise for Faster Clinical Study Start-Up in Drug Development

Why Many Global Drugs Never Reach Japan

Ready for ESG NextGen, or still submitting like it’s 2015?

Trial Designs: Non-inferiority vs. Superiority vs. Equivalence

Phoenix Roadshow 2026 – Florence

Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants

How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development

Seeing is Understanding: Best Practices for Visualizing Nonclinical Study Data

Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach

Newsletter sign up

Quick links

Solutions

Contact